Thrombin Inhibitors
Drug Safety Update
May 2023: Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment
October 2020: Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic
June 2020: Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents
June 2019: Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome
October 2013: New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼)- Risk of serious haemorrhage (clarified contraindications)
March 2013: Dabigatran (Pradaxa): contraindicated in patients with prosthetic heart valve(s) requiring anti-coagulant treatment
July 2012: Dabigatran (Pradaxa▼): risk of serious haemorrhage
NICE Guidance (see drug-specific links below)
NG158: Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, March 2020
CG196: Atrial fibrillation: diagnosis & management, June 2021
CG185: Acute coronary syndromes, Nov 2020
Dabigatran - for safety reasons should be used second line to other oral anticoagulants - see Factor Xa inhibitors.
Idarucizumab (Praxbind) is a specific reversal agent for dabigatran - see Antidotes and chelators.
| Pack |
|---|
| 10 capsule |
| 30 capsule |
| 60 capsule |
| Pack |
|---|
| 10 capsule |
| 30 capsule |
| 60 capsule |
| Pack |
|---|
| 60 capsule |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary